These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 26436935)
21. Augmented renal clearance, low β-lactam concentrations and clinical outcomes in the critically ill: an observational prospective cohort study. Huttner A; Von Dach E; Renzoni A; Huttner BD; Affaticati M; Pagani L; Daali Y; Pugin J; Karmime A; Fathi M; Lew D; Harbarth S Int J Antimicrob Agents; 2015 Apr; 45(4):385-92. PubMed ID: 25656151 [TBL] [Abstract][Full Text] [Related]
22. Exploration of the pre-analytical stability of β-lactam antibiotics in plasma and blood--implications for therapeutic drug monitoring and pharmacokinetic studies. Carlier M; De Waele JJ; Verstraete AG; Stove V Clin Chem Lab Med; 2015 Aug; 53(9):e227-30. PubMed ID: 25381954 [No Abstract] [Full Text] [Related]
23. Empirical models for dosage optimization of four beta-lactams in critically ill septic patients based on therapeutic drug monitoring of amikacin. Delattre IK; Musuamba FT; Verbeeck RK; Dugernier T; Spapen H; Laterre PF; Wittebole X; Cumps J; Taccone FS; Vincent JL; Jacobs F; Wallemacq PE Clin Biochem; 2010 Apr; 43(6):589-98. PubMed ID: 20036226 [TBL] [Abstract][Full Text] [Related]
24. Antibiotic Stewardship and Therapeutic Drug Monitoring of β-Lactam Antibiotics: Is There a Link? An Opinion Paper. Richter DC; Heininger A; Chiriac U; Frey OR; Rau H; Fuchs T; Röhr AC; Brinkmann A; Weigand MA Ther Drug Monit; 2022 Feb; 44(1):103-111. PubMed ID: 34857694 [TBL] [Abstract][Full Text] [Related]
25. A narrative review of predictors for β-lactam antibiotic exposure during empirical treatment in critically ill patients. Abdulla A; Ewoldt TMJ; Purmer IM; Muller AE; Gommers D; Endeman H; Koch BCP Expert Opin Drug Metab Toxicol; 2021 Apr; 17(4):359-368. PubMed ID: 33463382 [TBL] [Abstract][Full Text] [Related]
26. Augmented renal clearance in critically ill patients: etiology, definition and implications for beta-lactam dose optimization. Sime FB; Udy AA; Roberts JA Curr Opin Pharmacol; 2015 Oct; 24():1-6. PubMed ID: 26119486 [TBL] [Abstract][Full Text] [Related]
27. Therapeutic drug monitoring of beta-lactams for critically ill patients: unwarranted or essential? Roberts JA; Hope WW; Lipman J Int J Antimicrob Agents; 2010 May; 35(5):419-20. PubMed ID: 20189777 [No Abstract] [Full Text] [Related]
28. Dose optimization of β-lactam antibiotics in children: from population pharmacokinetics to individualized therapy. Ngougni Pokem P; Vanneste D; Schouwenburg S; Abdulla A; Gijsen M; Dhont E; Van der Linden D; Spriet I; De Cock P; Koch B; Van Bambeke F; Wijnant GJ Expert Opin Drug Metab Toxicol; 2024 Aug; 20(8):787-804. PubMed ID: 39078238 [TBL] [Abstract][Full Text] [Related]
29. Implementation of a β-lactam therapeutic drug monitoring program: Experience from a large academic medical center. Venugopalan V; Hamza M; Santevecchi B; DeSear K; Cherabuddi K; Peloquin CA; Alshaer MH Am J Health Syst Pharm; 2022 Sep; 79(18):1586-1591. PubMed ID: 35704702 [TBL] [Abstract][Full Text] [Related]
30. Protein binding of β-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations? Wong G; Briscoe S; Adnan S; McWhinney B; Ungerer J; Lipman J; Roberts JA Antimicrob Agents Chemother; 2013 Dec; 57(12):6165-70. PubMed ID: 24080664 [TBL] [Abstract][Full Text] [Related]
31. Population pharmacokinetics of four β-lactams in critically ill septic patients comedicated with amikacin. Delattre IK; Musuamba FT; Jacqmin P; Taccone FS; Laterre PF; Verbeeck RK; Jacobs F; Wallemacq P Clin Biochem; 2012 Jul; 45(10-11):780-6. PubMed ID: 22503878 [TBL] [Abstract][Full Text] [Related]
33. How can we ensure effective antibiotic dosing in critically ill patients receiving different types of renal replacement therapy? Jamal JA; Mueller BA; Choi GY; Lipman J; Roberts JA Diagn Microbiol Infect Dis; 2015 May; 82(1):92-103. PubMed ID: 25698632 [TBL] [Abstract][Full Text] [Related]
34. Therapeutic drug monitoring of the β-lactam antibiotics: what is the evidence and which patients should we be using it for? Huttner A; Harbarth S; Hope WW; Lipman J; Roberts JA J Antimicrob Chemother; 2015 Dec; 70(12):3178-83. PubMed ID: 26188037 [TBL] [Abstract][Full Text] [Related]
35. Can we transfer pharmacokinetics/pharmacodynamics of antimicrobials into clinical practice? Scaglione F Int J Antimicrob Agents; 2015 Dec; 46 Suppl 1():S40-2. PubMed ID: 26607342 [TBL] [Abstract][Full Text] [Related]
36. Rapid quantification of six β-lactams to optimize dosage regimens in severely septic patients. Wolff F; Deprez G; Seyler L; Taccone F; Hites M; Gulbis B; Vincent JL; Jacobs F; Cotton F Talanta; 2013 Jan; 103():153-60. PubMed ID: 23200371 [TBL] [Abstract][Full Text] [Related]
37. Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients. Fournier A; Eggimann P; Pagani JL; Revelly JP; Decosterd LA; Marchetti O; Pannatier A; Voirol P; Que YA Burns; 2015 Aug; 41(5):956-68. PubMed ID: 25678084 [TBL] [Abstract][Full Text] [Related]
38. Therapeutic Drug Monitoring of Beta-Lactams and Other Antibiotics in the Intensive Care Unit: Which Agents, Which Patients and Which Infections? Muller AE; Huttner B; Huttner A Drugs; 2018 Mar; 78(4):439-451. PubMed ID: 29476349 [TBL] [Abstract][Full Text] [Related]
39. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper Abdul-Aziz MH; Alffenaar JC; Bassetti M; Bracht H; Dimopoulos G; Marriott D; Neely MN; Paiva JA; Pea F; Sjovall F; Timsit JF; Udy AA; Wicha SG; Zeitlinger M; De Waele JJ; Roberts JA; ; ; ; Intensive Care Med; 2020 Jun; 46(6):1127-1153. PubMed ID: 32383061 [TBL] [Abstract][Full Text] [Related]
40. Biosensors and nanobiosensors for therapeutic drug and response monitoring. McKeating KS; Aubé A; Masson JF Analyst; 2016 Jan; 141(2):429-49. PubMed ID: 26631282 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]